Sacuva49 mg+51 mg

Sacuva is a fixed-dose combination of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan), classified as an angiotensin receptor-neprilysin inhibitor (ARNI).

• Established/FDA-approved use (adults): Sacuva is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure, generally in patients with reduced ejection fraction. It is most beneficial when ejection fraction is below normal.
• Established/FDA-approved use (pediatrics): Sacuva is indicated for the treatment of symptomatic heart failure due to systemic left ventricular systolic dysfunction in children aged 1 year and older.
• Guideline-supported use: Major heart failure guidelines (e.g., ACC/AHA/HFSA) recommend Sacuva as a preferred first-line agent (in place of an ACE inhibitor or ARB) in patients with heart failure with reduced ejection fraction who can tolerate it, as part of guideline-directed medical therapy alongside a beta-blocker, mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.
• Combination therapy requirement: Sacuva is used together with other heart failure therapies (diuretics, beta-blockers, mineralocorticoid receptor antagonists) as clinically indicated; it is not a substitute for comprehensive heart failure management.

Sacuva is not indicated in patients who are unable to tolerate an ACE inhibitor or ARB due to a history of angioedema, or in patients with severe hepatic impairment.

Sacubitril + Valsartan is available as film-coated tablets containing sacubitril and valsartan in fixed ratios (approximately 1:1 by molar equivalence), typically supplied as sacubitril/valsartan 24/26 mg, 49/51 mg, and 97/103 mg tablets. Pediatric oral pellet (sprinkle) formulations of lower strengths are also available in some markets for weight-based dosing in children.

Each tablet strength is designed for twice-daily oral dosing, with the two active moieties (sacubitril, a prodrug that is converted to the active neprilysin inhibitor sacubitrilat, and valsartan, an angiotensin II receptor blocker) acting complementarily on the neurohormonal pathways involved in heart failure.

Sacuva is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) used in the management of chronic heart failure. It combines two mechanisms of action in a single molecule complex: inhibition of neprilysin, an enzyme that degrades natriuretic peptides, and blockade of the angiotensin II type 1 (AT1) receptor.

By simultaneously enhancing the beneficial natriuretic peptide system and suppressing the harmful renin-angiotensin-aldosterone system (RAAS), Sacuva produces greater reductions in the risk of cardiovascular death and heart failure hospitalization compared with ACE inhibitor therapy alone, as demonstrated in large randomized controlled trials.

Sacuva is taken orally, twice daily, and dosing is individualized based on prior ACE inhibitor/ARB use, blood pressure, and renal/hepatic function.

Sacuva belongs to the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) class, a combination of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan). It is used primarily in cardiology for the management of heart failure with reduced ejection fraction.

Sacubitril + Valsartan works through two complementary mechanisms:

• Sacubitril is a prodrug that is metabolized to sacubitrilat (LBQ657), which inhibits neprilysin (neutral endopeptidase), the enzyme responsible for degrading natriuretic peptides (ANP, BNP), bradykinin, and other vasoactive peptides. Inhibiting neprilysin increases levels of these peptides, promoting natriuresis, diuresis, vasodilation, and reduced cardiac remodeling, while reducing sympathetic tone.
• Valsartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive, aldosterone-secreting, and sodium-retaining effects of angiotensin II, thereby reducing blood pressure and cardiac afterload.

Combining neprilysin inhibition with an ARB (rather than an ACE inhibitor) avoids the excessive bradykinin-mediated angioedema risk that would occur if neprilysin inhibition were combined with an ACE inhibitor. Peak plasma concentrations of sacubitril and valsartan occur within 0.5-1 hour and 1.5-4 hours respectively; both components are highly protein bound and have half-lives of approximately 1.4 hours (sacubitril) and 9.9 hours (valsartan), supporting twice-daily dosing.

Sacuva is administered orally, twice daily, approximately 12 hours apart, with or without food. Tablets should be swallowed whole; the pediatric oral pellet (sprinkle) formulation may be mixed with a small amount of soft food or liquid immediately before administration, per product-specific instructions. Do not administer Sacuva together with an ACE inhibitor, and observe the required 36-hour washout period when switching to or from an ACE inhibitor.

The following are well-documented, clinically significant interactions with Sacuva:

• ACE inhibitors: Concomitant use is contraindicated due to a markedly increased risk of life-threatening angioedema; a minimum 36-hour washout period is required when switching between Sacuva and an ACE inhibitor in either direction.
• Aliskiren: Contraindicated in patients with diabetes; avoid combination in patients with renal impairment (eGFR <60 mL/min/1.73m²) due to increased risk of hyperkalemia, hypotension, and renal impairment.
• Other angiotensin receptor blockers (ARBs): Avoid concomitant use, as Sacuva already contains an ARB (valsartan); combining increases risk of hyperkalemia, hypotension, and renal impairment without added benefit.
• Potassium-sparing diuretics, potassium supplements, and salt substitutes containing potassium: May increase the risk of hyperkalemia; monitor serum potassium.
• NSAIDs (including selective COX-2 inhibitors): May reduce the antihypertensive effect and worsen renal function, particularly in elderly, volume-depleted, or renally impaired patients; monitor renal function.
• Lithium: Increased serum lithium concentrations and lithium toxicity have been reported when lithium is combined with ARBs or neprilysin inhibitors; monitor lithium levels closely.
• Statins (e.g., atorvastatin, simvastatin): Sacubitril modestly increases statin exposure; clinical significance is generally limited but monitor for statin-related adverse effects.

The most commonly reported adverse reactions with Sacuva (observed in large controlled trials) include:

• Hypotension (very common, especially at treatment initiation and up-titration)
• Hyperkalemia (common)
• Cough (common)
• Dizziness (common)
• Renal impairment / increased serum creatinine (common)
• Fatigue
• Orthostatic hypotension and falls, particularly in elderly patients

Serious but less common: angioedema (potentially life-threatening; discontinue immediately if symptoms of swelling of the face, lips, tongue, glottis, larynx, or airway obstruction occur - see Precautions and Warnings), acute kidney injury, and severe hypotension leading to syncope.

Pregnancy: Sacuva is contraindicated in pregnancy. Drugs that act directly on the renin-angiotensin system, including the valsartan component of Sacuva, can cause fetal and neonatal injury or death when used during the second and third trimesters, including oligohydramnios, fetal renal impairment, skull hypoplasia, and fetal/neonatal death. When pregnancy is detected, Sacuva should be discontinued as soon as possible and the patient switched to an alternative therapy under physician guidance. Use only if clearly needed and no safer alternative exists, and only under close physician supervision; women of childbearing potential should be counseled on the risks and use of effective contraception.

Lactation: There is insufficient data on the presence of Sacuva in human milk; breastfeeding is generally not recommended during treatment due to the potential for serious adverse effects in a nursing infant. A physician should be consulted to weigh the benefits of breastfeeding against the mother's need for Sacuva therapy.

The following precautions apply to the use of Sacuva:

• Angioedema: Sacuva carries a risk of angioedema, which can be life-threatening if the airway is involved. Risk is higher in patients with a prior history of angioedema and in Black patients. Discontinue immediately and seek emergency care if signs of angioedema (facial, lip, tongue, or airway swelling) occur; do not re-administer Sacuva.
• Hypotension: Symptomatic hypotension may occur, particularly in patients who are volume- or salt-depleted, elderly, or have renal impairment. Correct volume/salt depletion before initiating therapy, and monitor blood pressure closely during initiation and up-titration.
• Renal function impairment: Sacuva can cause a decline in renal function, particularly in patients with renal artery stenosis, volume depletion, or pre-existing renal impairment. Monitor serum creatinine and potassium periodically; down-titrate or interrupt therapy if significant renal function decline occurs.
• Hyperkalemia: Monitor serum potassium periodically, especially in patients with renal impairment, diabetes, or those on potassium-sparing diuretics or potassium supplements.
• Dual RAAS blockade: Do not combine Sacuva with an ACE inhibitor or another ARB, and avoid combination with aliskiren (contraindicated in diabetics; avoid in renal impairment) - see Contraindications and Interactions.
• Not for use in severe hepatic impairment (Child-Pugh C).

Limited data are available on overdosage with Sacuva. Based on its pharmacology, the most likely effect of overdose is symptomatic hypotension; other possible effects include dizziness, bradycardia or tachycardia, renal impairment, and hyperkalemia. In case of suspected overdose, seek immediate medical attention or contact emergency services / a poison control center. Treatment is supportive, typically involving intravenous fluids to correct hypotension and monitoring of vital signs, renal function, and electrolytes. Due to high protein binding, Sacuva is not expected to be effectively removed by hemodialysis. Do not attempt to manage an overdose at home without medical guidance.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

• Pediatric use: Sacuva is approved for symptomatic heart failure due to left ventricular systolic dysfunction in children 1 year of age and older, with weight-based dosing and titration under specialist supervision. Safety and efficacy in children younger than 1 year have not been established.
• Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and younger patients, though elderly patients may be at greater risk of hypotension, falls, and renal function changes; use with appropriate monitoring.
• Renal impairment: No dose adjustment is needed for mild to moderate renal impairment; a lower starting dose is recommended for severe renal impairment (eGFR <30 mL/min/1.73m²) - see Dosage and Administration.
• Hepatic impairment: No dose adjustment needed for mild impairment (Child-Pugh A); a lower starting dose is recommended for moderate impairment (Child-Pugh B); Sacuva is not recommended in severe hepatic impairment (Child-Pugh C), biliary cirrhosis, or cholestasis.
• Pregnancy and lactation: See Pregnancy and Lactation section - contraindicated in pregnancy.

Sacuva is generally intended for long-term, often lifelong, use in patients with chronic heart failure, as part of ongoing guideline-directed medical therapy. Duration of treatment should be determined by the treating physician based on clinical response, tolerability, and overall heart failure management goals. Sacuva should not be stopped abruptly without medical advice, as this may worsen heart failure symptoms; if discontinuation is needed (e.g., due to intolerable side effects or pregnancy), this should be done under physician guidance with appropriate alternative therapy arranged.

Angiotensin Receptor-Neprilysin Inhibitor (ARNI); Neprilysin Inhibitor + Angiotensin II Receptor Blocker (ARB) combination

Sacubitril + Valsartan acts through dual inhibition of two counter-regulatory neurohormonal systems involved in heart failure. The sacubitril component inhibits neprilysin, preventing the breakdown of natriuretic peptides and other vasoactive substances, which enhances natriuresis, diuresis, vasodilation, and reduces cardiac remodeling. The valsartan component blocks the AT1 receptor, inhibiting the vasoconstrictive and sodium-retaining actions of angiotensin II. Together, these actions reduce cardiac preload and afterload, and counteract the maladaptive neurohormonal activation that drives heart failure progression, resulting in reduced risk of cardiovascular death and heart failure hospitalization.

Sacuva is approved for the treatment of symptomatic heart failure due to systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. Dosing is individualized based on body weight, using either tablet or oral pellet (sprinkle) formulations, with stepwise up-titration approximately every 2 weeks as tolerated, under the supervision of a pediatric cardiologist or heart failure specialist. Safety and efficacy have not been established in children younger than 1 year of age. As with adults, Sacuva must not be combined with an ACE inhibitor, and the 36-hour washout rule applies when switching between the two.